

CMO & CDMO

cphi.evapharma.com

2021



EVA PHARMA



About Us

At EVA Pharma, we pride ourselves on our innovation and our expertise, built on a heritage spanning over a hundred years.

We aim to offer our CMO and CDMO partners high-quality results, while also guaranteeing flexibility and cost-effectiveness.

Our experienced research and development team of over a hundred scientists is based at the largest dedicated site for pharmaceutical development and services in the MENA region, our EMA-approved manufacturing facility in Cairo, Egypt.

The state-of-the-art facility includes high-quality equipment and machinery and is fully compliant with GMP and GLP guidelines.

We have experience in a wide range of dosage forms, including vials, ampoules, tubes, capsules, tablets, sachets, effervescent, DPIs, syrups, BFS unidoses, BFA multidoses, ophthalmic drug formulations, WFI, cephalosporins, soft gelatin capsules, and patches. Our existing portfolio includes 165 products.

In addition, our international supply chain team and worldwide supplier network ensure our clients can obtain quality and competitively priced material in alignment with their project timelines.

Due to our significant capacity, we can offer flexibility in supply and in batch size.

We also offer serialization and a short lead time, allowing our partners to meet their deadlines.



Building Successful Partner- ships

We have a record of successful partnerships in a variety of areas.

EVA Pharma has operational in-licensing agreements in a number of countries, including Algeria, Bahrain, Egypt, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE.

We have also been recognized as the partner of choice by several multinational companies in Europe through out-licensing the company's unique eCTD dossiers, which are now registered in more than ten EU countries.


In 2019, we partnered with Gilead Sciences to become a licensed distributor for their HIV, HBV and HCV products in Africa, and in 2020 we acquired the license to manufacture and distribute Gilead's COVID-19 antiviral remdesivir, going on to export it to dozens of countries.

In addition, in 2020, EVA Group signed a strategic partnership agreement with Eli Lilly and Company to import, distribute, market and sell Lilly's portfolio of brands in Egypt.



Partner With Us

Our client partnerships span
the entire process of development,
from API to finished product.



EVA PHARMA
SECURING YOUR HEALTH

**Contact us to find solutions
that work for you.**

cphi.evapharma.com